Similar articles

• Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.

  Simnica D, Kobold S. Simnica D, et al. N Engl J Med. 2022 Aug 11;387(6):573. doi: 10.1056/NEJMc2208623. N Engl J Med. 2022. PMID: 35947720 No abstract available.
• T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen.

  Klebanoff CA. Klebanoff CA. Cancer Immunol Res. 2022 Aug 3;10(8):919. doi: 10.1158/2326-6066.CIR-22-0386. Cancer Immunol Res. 2022. PMID: 35767244
• Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.

  Linette GP, Becker-Hapak M, Skidmore ZL, Baroja ML, Xu C, Hundal J, Spencer DH, Fu W, Cummins C, Robnett M, Kaabinejadian S, Hildebrand WH, Magrini V, Demeter R, Krupnick AS, Griffith OL, Griffith M, Mardis ER, Carreno BM. Linette GP, et al. Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23662-23670. doi: 10.1073/pnas.1906026116. Epub 2019 Nov 4. Proc Natl Acad Sci U S A. 2019. PMID: 31685621 Free PMC article.
• Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.

  Li TJ, Wang WQ, Yu XJ, Liu L. Li TJ, et al. Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188384. doi: 10.1016/j.bbcan.2020.188384. Epub 2020 Jun 9. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32531324 Review.
• MHC class II restricted neoantigen: A promising target in tumor immunotherapy.

  Sun Z, Chen F, Meng F, Wei J, Liu B. Sun Z, et al. Cancer Lett. 2017 Apr 28;392:17-25. doi: 10.1016/j.canlet.2016.12.039. Epub 2017 Jan 16. Cancer Lett. 2017. PMID: 28104443 Review.